AIHealthcare Analytics

Synthetic Data Generation Methods

Three major generative model architectures are used for healthcare synthetic data: Conditional Tabular GAN (CTGAN), CopulaGAN, and Tabular Variational Autoencoder (TVAE). Evaluation on the Pima Indians Diabetes Dataset shows optimized models generate high-fidelity synthetic data with predictive accuracy comparable to real data, assessed using Pairwise Correlation Distance and Wasserstein Distance. GHOSTS (Generator of Hospital Time Series) generates realistic heterogeneous patient trajectories including time series with uneven sampling intervals, outperforming DoppelGANger and HALO on clinical prediction tasks trained on MIMIC-IV and eICU datasets.

Augmentation for Medical Imaging

A generative AI-based computer-aided diagnosis (CAD) system for ampullary lesions used latent diffusion to synthesize 500 images per class for data augmentation, achieving 91.57% overall diagnostic accuracy and improving adenoma sensitivity from 63.47% to 70.56% in a reader study across seven hospitals. Both expert and trainee endoscopists benefited from CAD support with reduced interobserver variability.

Clinical Trial Protocol Deviation Analysis

A combined statistical outlier detection and generative AI approach analyzed 578 clinical studies across 39,936 sites. Generative AI with hierarchical clustering automatically categorized protocol deviation narratives into 15 major categories and 47 specific topics through human-in-the-loop refinement. Independent validation using an LLM-as-judge approach achieved 88.7% accuracy (95% CI: 86.5%–90.6%).

Privacy and Regulatory Considerations

Generative models can comply with privacy laws by learning to synthesize patient data while ensuring data privacy. Key applications include overcoming data scarcity (e.g., GANs creating synthetic continuous glucose monitoring trajectories for diabetes), enabling privacy-preserving data sharing, and augmenting rare disease datasets. Clinical translation requires rigorous prospective validation; a systematic review found 92% of AIGC diabetes studies achieved technical validation but none demonstrated implementation maturity.